CoViD-19 Immunopathology and Immunotherapy
Francesco Chiappelli, Allen Khakshooy, Gillian Greenberg, Francesco Chiappelli, Allen Khakshooy, Gillian Greenberg
Abstract
New evidence on the T-cell immuno-pathology in patient's with Corona Virus Disease 2019 (CoViD-19) was reported by Diao et al. in MedRxiv (doi: 10.1101/2020.02.18.20024364) [1]. It reports observations on 522 patients with confirmed CoViD-19 symptomatology, compared to 40 control subjects. In brief, notable T cytopoenia was recorded by flow cytometry in the CD4+ and the CD8+ populations, which were significantly yet inversely correlated with remarkably increased serum levels of the pro-inflammatory cytokines IL-6, IL-10 and TNF-a. Flow cytometry established a progressive increase in the expression of programmed cell death marker-1 (PD-1) and T cell immunoglobulin and mucin domain 3 (Tim-3) as patients (n=14) deteriorated from prodromal to symptomatic CoViD-19 requiring intensive care. Here, we interpret these observations of Diao et al from our current understanding of T cell immunophysiology and immunopathology following an immune challenge in the form of sustained viral infection, as is the case in CoViD-19, with emphasis on exhausted T cells (Tex). Recent clinical trials to rescue Tex show promising outcomes. The relevance of these interventions for the prevention and treatment of CoViD-19 is discussed. Taken together, the data of Diao et al could proffer the first glimpse of immunopathology and possible immunotherapy for patients with CoViD-19.
Keywords: Corona Virus Disease 2019 (CoViD-19); T cell exhaustion (Tex) markers, programmed cell death marker 1 (CD279 - PD-1); T cell immunoglobulin and mucin domain-3 (CD366 - Tim-3); clinical trials; cytokine storm.
© 2020 Biomedical Informatics.
References
- Diao B, et al. medRxiv preprint. 2020 doi10.1101/2020.02.18.20024364.
- Chiappelli F, et al. Bioinformation. 2018;14:201.
- Yi JS, et al. Immunol. 2010;129:474.
- Wherry EJ. Nature Immunol. 2011;12:492.
- Saeidi A, et al. Front Immunol. 2018;9:2569.
- Hashimoto M, et al. Annu Rev Med. 2018;69:301.
- McLane LM, et al. Annu Rev Immunol. 2019;37:457.
- Ioannidis JP, et al. PLoS Biol. 2015;13:e1002264.
- Winkler F, Bengsch B. Front Immunol. . 2020;10:3039.
- Lin X, et al. Eur J Med Chem. 2020;186:111876.
- David P, et al. Front. Immunol. 2019;10:54.
- Kamphorst AO, et al. Science. 2017;355:1423.
- Hui E, et al. Science. 2017;355:1428.
- Kasakovski D, et al. J Hematol Oncol. 2018;11:91.
Source: PubMed